Traumatic PVR prevention and treatment via composite drug film
Abstract This study aimed to develop a composite sustained-release drug film by incorporating triamcinolone acetonide (TA) and daunorubicin (DNR) into a poly-L-lactide caprolactone (P(LLA-CL)) matrix, and to evaluate its in vitro release characteristics, in vivo biocompatibility, and therapeutic efficacy in the treatment of traumatic proliferative vitreoretinopathy (TPVR). P(LLA-CL) was dissolved in hexafluoroisopropanol, weighed TA and DNR powder, and added it to the P(LLA-CL) solution, and then electrospinning was performed on these materials to prepare P(LLA-CL)-TA, P(LLA-CL)-DNR, and P(LLA-CL)-TA-DNR composite drug films. In vitro release experiments were performed on drug films (4 × 8 mm) and corresponding drug powders placed in phosphate-buffered saline (PBS). At fixed time points, samples were collected and drug content was calculated by HPLC to record the cumulative drug release curve. The in vivo safety of the drug films was evaluated by suturing the drug films onto the rabbit eyes sclera, 5 mm away from the limbus, and then observing slit-lamp biomicroscopy, intraocular pressure (IOP), and histopathological changes at fixed time points from 1 week to 6 months after suturing. TPVR was constructed by scleral injury and autologous blood injection, and the rabbits were randomly divided into model, control, P(LLA-CL)-TA, P(LLA-CL)-DNR, and composite drug film groups. The observation indices were fundus photography, HE staining, and immunohistochemistry (IHC) analysis of inflammatory factors TNF-α and TGF-β. In vitro release experiment results showed that the P(LLA-CL)-TA and P(LLA-CL)-DNR drug films released the drugs for 156 and 135 days, and the cumulative drug release rates reached 88.41% and 92.68%, respectively. The composite P(LLA-CL)-TA-DNR drug film released TA and DNR for 141 days (91.54%) and 129 days (89.31%) respectively, which were greatly prolonged compared with the release time of the drugs powders (48 days and 4 days for TA and DNR, respectively). In vivo experiment results showed that no ocular toxicity or IOP elevation was induced by the drug films. The gradual degradation of drug films was observed during the six-month observation period. In therapeutic application, the composite drug film reduced the retinal folding, preretinal membrane formation and TNF-α mean optical density at 2 weeks [(0.426 ± 0.036) vs. (0.518 ± 0.043) in the model group, P < 0.0001] and at 4 weeks [(0.460 ± 0.040) vs. (0.537 ± 0.029), P = 0.0003], and improved the vitreous hemorrhage ( P = 0.0402). P(LLA-CL)-TA-DNR composite drug film can achieve sustained release of therapeutic agents for up to five months. The drug film exhibits a good safety profile, and showed preliminary therapeutic potential to attenuate TPVR progression via suppressing inflammatory response and cellular proliferation. Compared with single-drug films, the composite film showed marginal improvement of vitreous hemorrhage absorption and reduced retinal proliferation.
Authors
- Yuzhen Liu (ORCID: https://orcid.org/0000-0002-7299-4708)
- Kaihui Nan (ORCID: https://orcid.org/0000-0002-6592-1682)
- Mei Chen (ORCID: https://orcid.org/0000-0003-2368-5105)
- Ting Zhu
- Xiaolin Wang
- Jie Liu
Institutions
- Central South University (CN)
- Wenzhou Medical University (CN)
- Affiliated Eye Hospital of Wenzhou Medical College (CN)
- Second Xiangya Hospital of Central South University (CN)
- Aier Eye Hospital Group (China) (CN)
- Joint Shantou International Eye Center (CN)
Publication Details
- Journal
- Scientific Reports
- Published
- 2026-11-15
- DOI
- https://doi.org/10.1038/s41598-026-78242-6
- Primary Topic
- Advanced Drug Delivery Systems
- Type
- article
- Field-Weighted Citation Impact
- 0.00